📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Viking Therap(VKTX.US) Viking Therapeutics Launches Phase 1 Trial for New Weight-Loss Drug VK3019
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ 𝐕𝐢𝐤𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 initiated a 𝐏𝐡𝐚𝐬𝐞 𝟏 trial of weight-loss candidate VK3019.➤ VK3019 is a 𝐝𝐮𝐚𝐥 𝐚𝐦𝐲𝐥𝐢𝐧 and 𝐜𝐚𝐥𝐜𝐢𝐭𝐨𝐧𝐢𝐧 receptor agonist (DACRA).➤ Trial follows 𝐅𝐃𝐀 clearance of VK3019's Investigational New Drug application.➤ Study will evaluate 𝐬𝐚𝐟𝐞𝐭𝐲, 𝐭𝐨𝐥𝐞𝐫𝐚𝐛𝐢𝐥𝐢𝐭𝐲, and pharmacokinetics in adults with BMI ≥ 30.➤ Exploratory assessments include changes in 𝐛𝐨𝐝𝐲 𝐰𝐞𝐢𝐠𝐡𝐭 after a single dose.➤ Preclinical data showed up to 𝟖% 𝐛𝐨𝐝𝐲-𝐰𝐞𝐢𝐠𝐡𝐭 reduction within 72 hours in animal studies.➤ Viking is also conducting 𝐏𝐡𝐚𝐬𝐞 𝟑 VANQUISH trials for obesity drug VK2735.➤ Company plans to launch a 𝐏𝐡𝐚𝐬𝐞 𝟑 trial of oral VK2735 later in 2026.👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:➤ VK3019 expands Viking's pipeline in the rapidly growing 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 treatment market.➤ DACRA therapies could complement 𝐆𝐋𝐏-𝟏 and GLP-1/GIP weight-loss medicines.➤ Success could provide additional 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐰𝐞𝐢𝐠𝐡𝐭-𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 options for patients.👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:➤ "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧, Ph.D., Chief Executive Officer of Viking Therapeutics.➤ "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.➤ "Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.

